Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Interest & Investment Income (2016 - 2017)

Historic Interest & Investment Income for Pharma (IGC) over the last 9 years, with Q3 2017 value amounting to $100.0.

  • Pharma's Interest & Investment Income fell 1228.07% to $100.0 in Q3 2017 from the same period last year, while for Sep 2017 it was $2228.0, marking a year-over-year increase of 136.49%. This contributed to the annual value of $1744.0 for FY2017, which is 1635.49% down from last year.
  • Latest data reveals that Pharma reported Interest & Investment Income of $100.0 as of Q3 2017, which was down 1228.07% from $114.0 recorded in Q3 2016.
  • Over the past 5 years, Pharma's Interest & Investment Income peaked at $27509.0 during Q1 2013, and registered a low of $70.0 during Q4 2015.
  • Over the past 5 years, Pharma's median Interest & Investment Income value was $1919.0 (recorded in 2013), while the average stood at $3572.3.
  • As far as peak fluctuations go, Pharma's Interest & Investment Income soared by 38745.52% in 2013, and later plummeted by 9565.22% in 2015.
  • Pharma's Interest & Investment Income (Quarter) stood at $1824.0 in 2013, then fell by 11.73% to $1610.0 in 2014, then plummeted by 95.65% to $70.0 in 2015, then skyrocketed by 62.86% to $114.0 in 2016, then decreased by 12.28% to $100.0 in 2017.
  • Its Interest & Investment Income stands at $100.0 for Q3 2017, versus $114.0 for Q3 2016 and $2014.0 for Q1 2016.